WEST CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Aug. 15, 2005–Dermisonics, Inc. (OTCBB:DMSI), a medical device company with its focus on the development of an ultrasonically assisted transdermal drug-delivery technology, announced today that its has formed a sales and marketing alliance with PharmaVentures Ltd (Oxford, UK) to promote its groundbreaking U-Strip transdermal drug-delivery device.

PharmaVentures, http://www.pharmaventures.com, is a specialist pharmaceutical consultancy serving the business needs of both emerging and established healthcare companies.

Specifically, Dermisonics is offering pharmaceutical companies a new U-Strip Drug Screening Program whereby select compounds can be screened for their potential to be delivered via the U-Strip Ultrasonic Drug Delivery System. These screening studies include three major investigations:

1) Exposure of the compound to ultrasonic energy to determine if
there are any degradation effects caused by the ultrasound.

2) Patch release trials to determine loading factors upon select
patch designs, and the dose released from the patch in
response to ultrasonic stimulus.

3) Skin permeation trials whereby the drug-loaded patch is applied
to human whole skin to determine the dose delivery factors.

PharmaVentures and Dermisonics will seek to secure screening contracts over the next several months from large multinational pharmaceutical concerns. The purpose of the screening process is to identify the next generation of drug candidates for the Company’s ultrasonic drug delivery system. Management hopes the program will lead to other strategic partnerships as viable products emerge from the screening program. For pharmaceutical sponsors, this service enables them to speed drug discovery by focusing upon an alternative and novel delivery method, allowing them to recapture their investment in development stage compounds that have not proven effective with traditional delivery methods.

About Dermisonics, Inc.

Dermisonics Inc. is a medical device company that is focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of heavy molecular drugs into the system. The U-Strip(TM) is a drug delivery system incorporating a transdermal patch in combination with microelectronics and ultrasonic technology. Tests have shown that this system facilitates the transdermal delivery of Insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size.

About PharmaVentures Ltd.

PharmaVentures is a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas – PharmaVentures Consulting and PharmaVentures Intelligence, we work with our clients to drive greater value from their deals. Based in Oxford, UK the company employs over 30 people and has offices in the USA.